Exelixis
EXEL
#1814
Rank
โ‚น1.046 T
Marketcap
โ‚น3,889
Share price
2.80%
Change (1 day)
36.65%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): โ‚น205.34

According to Exelixis's latest financial reports the company's current EPS (TTM) is โ‚น217.68. In 2023 the company made an earnings per share (EPS) of โ‚น59.75 an increase over its 2022 EPS that were of โ‚น52.13.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)โ‚น205.34
2023โ‚น59.7514.61%
2022โ‚น52.13-22.97%
2021โ‚น67.68100%
2020โ‚น33.84-65.09%
2019โ‚น96.95-53.91%
2018โ‚น210.36333.96%
2017โ‚น48.48-260.61%
2016-โ‚น30.18-58.75%
2015-โ‚น73.17-42.45%
2014-โ‚น127.135.3%
2013-โ‚น120.73

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
โ‚น954.82 338.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น157.32-27.73%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚น1,192 447.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
โ‚น338.93 55.70%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚น694.55 219.07%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น271.65 24.79%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
โ‚น328.89 51.09%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-โ‚น335.67-254.20%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-โ‚น76.83-135.29%๐Ÿ‡บ๐Ÿ‡ธ USA